Clinical trials: Adult ADHD
Attention-Deficit/Hyperactivity Disorder, ADHD
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
- Trial name
- NCT01458340
- Testing
- TD-9855
- Where
- 17 sites in United States
- Volunteers
- 295 people
- Sponsor
- Theravance Biopharma
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
ADHD
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
- Trial name
- NCT05683249
- Testing
- NRCT-101-SR
- Where
- 9 sites in United States
- Volunteers
- 223 people
- Sponsor
- Neurocentria, Inc.
ADHD With Sleep Onset Insomnia
Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia
Primary: We hypothesize a clinically significant improvement in sleep latency, sleep-onset and total sleep time measures in adults with ADHD when given a trial of Ramelteon compared to placebo.
- Trial name
- NCT00622427
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Attention Deficit Hyperactivity Disorder
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120 mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for…
- Trial name
- NCT00530335
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Investigating the Effect of Vortioxetine in Adult ADHD Patients
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
- Trial name
- NCT02327013
- Testing
- vortioxetine 10 mg tablet, vortioxetine 20 mg tablet
- Where
- 15 sites in United States
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
ADHD
A Novel Device for the Management of ADHD
This is a 2-months study, where eligible ADHD adult participants will be provided with personalized VIZO glasses.
- Trial name
- NCT05777785
- Testing
- VIZO Glasses
- Where
- Israel
- Volunteers
- 108 people
- Sponsor
- VIZO Specs Ltd
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.
- Trial name
- NCT02604407
- Testing
- SHP465 12.5mg capsules (one capsule daily), SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
- Where
- 45 sites in United States
- Volunteers
- 275 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD.
- Trial name
- NCT02547428
- Testing
- CTN SR
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.
The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating Attention Deficit Hyperactivity Disorder (ADHD) in adults.
- Trial name
- NCT01873729
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Attention-Deficit/Hyperactivity Disorder
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a…
- Trial name
- NCT00877487
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 55 sites in United States
- Volunteers
- 123 people
- Sponsor
- Shire
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning…
- Trial name
- NCT02096952
- Testing
- Methylphenidate extended-release liquid formulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
Attention Deficit Hyperactivity Disorder
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Although Attention Deficit/ Hyperactive Disorder (ADHD) is a common comorbidity in individuals diagnosed with Substance Use Disorder (SUD), little data currently exists on the utility of screening tools in large samples of adult…
- Trial name
- NCT00953862
- Testing
- Atomoxetine
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity (ADHD)
Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD)
This study will test the effects of transcranial magnetic stimulation (TMS) on clinical measures of ADHD symptoms.
- Trial name
- NCT03663179
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
The purpose of this study is to a) assess the efficacy of omega-3 fatty acids in the treatment of Deficient Emotional Self-Regulation (DESR) among stimulant treated Attention Deficit Hyperactivity Disorder (ADHD) adults, b)…
- Trial name
- NCT01399827
- Testing
- ADHD Medication, Omega-3 Fatty Acids
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital